The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Open accessAbstract
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics. Particularly, the PD-L1 antibody therapy has shown the efficiency in blocking membrane PD-L1 and efficacy in treating some advanced carcinoma. However, this therapy has limited effects on many solid tumors, suspecting to be relevant to PD-L1 located in other cellular compartments, where they play additional roles and are associated with poor prognosis. In this review, we highlight the advances of 3 current strategies on PD-1/PD-L1 based immunotherapy, summarize cellular distribution of PD-L1, and review the versatile functions of intracellular PD-L1. The intracellular distribution and function of PD-L1 may indicate why not all antibody blockade is able to fully stop PD-L1 biological functions and effectively inhibit tumor growth. In this regard, gene silencing may have advantages over antibody blockade on suppression of PD-L1 sources and functions. Apart from cancer cells, PD-L1 silencing on host immune cells such as APC and DC can also enhance T cell immunity, leading to tumor clearance. Moreover, the molecular regulation of PD-L1 expression in cells is being elucidated, which helps identify potential therapeutic molecules to target PD-L1 production and improve clinical outcomes. Based on our understandings of PD-L1 distribution, regulation, and function, we prospect that the more effective PD-L1-based cancer immunotherapy will be combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · cited 1×
“As one of the major threats to public health worldwide, cancer is responsible for millions of deaths annually, with a high morbidity (5).”
BackgroundAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Functionalized Carbon Nanotubes for Plasmid DNA Gene Delivery
Pantarotto, D., Singh, R., McCarthy, D., Erhardt, M., Briand, J., Prato, M., Kostarelos, K., & Bianco, A. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200460437 · Cited by 1,091
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3153 · Cited by 642
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Baxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 578
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485
Chae, Y. K., Arya, A., Iams, W., Cruz, M. R., Chandra, S., Choi, J., & Giles, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0349-3 · Cited by 445
Gandini, S., Massi, D., & Mandalà, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.001 · Cited by 378
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Application of calcium phosphatenanoparticles in biomedicine
Epple, M., Ganesan, K., Heumann, R., Klesing, J., Kovtun, A., Neumann, S., & Sokolova, V. (2010) · J. Mater. Chem. · doi:10.1039/b910885h · Cited by 333
Ma, W., Gilligan, B. M., Yuan, J., & Li, T. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0277-y · Cited by 327
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse
Zou, S.-M., Erbacher, P., Remy, J.-S., & Behr, J.-P. (2000) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(200003/04)2:2<128::aid-jgm95>3.0.co;2-w · Cited by 317
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles
Li, L., Gu, W., Chen, J., Chen, W., & Xu, Z. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.095 · Cited by 304
Self-citationSoluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Zhu, X., & Lang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18311 · Cited by 303
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., Song, W., Chen, Y., OuYang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 287
Rewired ERK-JNK Signaling Pathways in Melanoma
Lopez-Bergami, P., Huang, C., Goydos, J. S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K. S. M., Mahale, A., Eroshkin, A., Aaronson, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.009 · Cited by 286
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3694 · Cited by 243
Manegold, C., Dingemans, A.-M. C., Gray, J. E., Nakagawa, K., Nicolson, M., Peters, S., Reck, M., Wu, Y.-L., Brustugun, O. T., Crinò, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 242
Self-citationGhebeh, H., Lehe, C., Barhoush, E., Al-Romaih, K., Tulbah, A., Al-Alwan, M., Hendrayani, S.-F., Manogaran, P., Alaiya, A., Al-Tweigeri, T., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2605 · Cited by 234
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., Liu, R., Tang, A., Li, X., Liu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9659 · Cited by 226
Cubillos-Ruiz, J. R., Engle, X., Scarlett, U. K., Martinez, D., Barber, A., Elgueta, R., Wang, Nesbeth, Y., Durant, Gewirtz, A. T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37716 · Cited by 208
Satelli, A., Batth, I. S., Brownlee, Z., Rojas, C., Meng, Q. H., Kopetz, S., & Li, S. (2016) · Scientific Reports · doi:10.1038/srep28910 · Cited by 203
Kondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuji, T., Shimizu, M., Shinya, E., Takahashi, H., Tamada, K., Chen, L., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255125 · Cited by 201
Chowdhury, S., Veyhl, J., Jessa, F., Polyakova, O., Alenzi, A., MacMillan, C., Ralhan, R., & Walfish, P. G. (2016) · Oncotarget · doi:10.18632/oncotarget.8698 · Cited by 193
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179 · cited 1×
“Meanwhile, the structures of these PD-L1 proteins are versatile, with some lacking transmembrane motifs and the potential of glycosylated modification or dimerization (19, 26, 27).”
BackgroundTeo, P. Y., Yang, C., Whilding, L. M., Parente‐Pereira, A. C., Maher, J., George, A. J. T., Hedrick, J. L., Yang, Y. Y., & Ghaem‐Maghami, S. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500089 · Cited by 172
Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.01.006 · Cited by 171
Hobo, W. A., Maas, F., Adisty, N., de Witte, T., Schaap, N. P., van der Voort, R., & Dolstra, H. (2010) · Blood · doi:10.1182/blood-2010-04-278739 · Cited by 167
Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3502 · Cited by 162
Koh, J., Jang, J.-Y., Keam, B., Kim, S., Kim, M., Go, H., Kim, T. M., Kim, D., Kim, C. W., Jeon, Y. K., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108514 · Cited by 159
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 159
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity
Jia, L., Xi, Q., Wang, H., Zhang, Z., Liu, H., Cheng, Y., Guo, X., Zhang, J., Zhang, Q., Zhang, L., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.074 · Cited by 159
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
Du, S., McCall, N. S., Park, K., Guan, Q., Fontina, P., Ertel, A., Zhan, T., Dicker, A. P., & Lü, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408747 · Cited by 153
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 149
Soluble B7-H1: Differences in production between dendritic cells and T cells
Frigola, X., Inman, B. A., Krco, C. J., Liu, X., Harrington, S. M., Bulur, P. A., Dietz, A. B., Dong, H., & Kwon, E. D. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.11.001 · Cited by 146
Ning, Y. M., Suzman, D. L., Maher, V. E., Zhang, L., Tang, S. W., Ricks, T. K., Palmby, T. R., Fu, W., Liu, Q., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0087 · Cited by 142
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
Yao, H., Wang, H., Li, C., Fang, J.-Y., & Xu, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01774 · Cited by 141
Li, K., & Tian, H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1440400 · Cited by 140
Synergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139
Ukpo, O. C., Thorstad, W. L., & Lewis, J. S. (2012) · Head and Neck Pathology · doi:10.1007/s12105-012-0406-z · Cited by 131
Mahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 131
Hobo, W. A., Novobrantseva, T. I., Fredrix, H., Wong, J., Milstein, S., Epstein-Barash, H., Liu, J., Schaap, N. P., van der Voort, R., & Dolstra, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1334-1 · Cited by 130
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 126
Yang, Z., & Tam, K. Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22955 · Cited by 116
Luo, X., Peng, X., Hou, J., Wu, S., Shen, J., & Wang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s137245 · Cited by 111
He, X., Xu, L., & Liu, Y. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00086.x · Cited by 90
Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Luke, J. J., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2197 · Cited by 89
He, R. L., Ding, W., Viswanatha, D. S., Chen, D., Shi, M., Dyke, D. L. V., Tian, S., Dao, L. N., Parikh, S. A., Shanafelt, T. D., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001077 · Cited by 83
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
Liao, Y., Chen, L., Feng, Y., Shen, J. K., Gao, Y., Cote, G. M., Choy, E., Harmon, D. C., Mankin, H. J., Hornicek, F. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16326 · Cited by 81
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells
Qu, Q.-X., Xie, F., Huang, Q. M., & Zhang, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484109 · Cited by 80
Qin, X., Liu, C., Zhou, Y., & Wang, G. (2010) · PubMed · Cited by 79
A dimeric structure of PD-L1: functional units or evolutionary relics?
Chen, Y., Liu, P., Gao, F., Cheng, H. D., Qi, J., & Gao, G. F. (2010) · Protein & Cell · doi:10.1007/s13238-010-0022-1 · Cited by 77
Chen, T., Wu, C., Wang, C., Hsu, W., Yang, T., Lou, P., Ko, J., & Chang, Y. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.08.011 · Cited by 77
Targeting hypoxia at the forefront of anticancer immune responses
Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70
Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential
Clark, C. A., Gupta, H. B., & Curiel, T. J. (2017) · Autophagy · doi:10.1080/15548627.2017.1280223 · Cited by 59
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma
Hua, D., Sun, J., Mao, Y., Chen, L.-J., Wu, Y.-Y., & 张学光 (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i9.971 · Cited by 54
Self-citationGu, W., Zou, H., Li, L., Carcedo, I. G., Xu, Z. P., & Monteiro, M. J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s100744 · Cited by 53
Self-citationvan der Waart, A. B., Fredrix, H., van der Voort, R., Schaap, N. P., Hobo, W. A., & Dolstra, H. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1668-6 · Cited by 50
Roeven, M. W. H., Hobo, W. A., van der Voort, R., Fredrix, H., Norde, W. J., Teijgeler, K., Ruiters, M. H. J., Schaap, N. P., & Dolstra, H. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000071 · Cited by 47
siRNA and Cancer Immunotherapy
Ghafouri‐Fard, S., & Ghafouri-Fard, S. (2012) · Immunotherapy · doi:10.2217/imt.12.87 · Cited by 42
Liang, M., Hui, Y., & Fu, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.028 · Cited by 42
Zhang, W., Pang, Q., Yan, C., Wang, Q., Yang, J., Yu, S., Liu, X., Yuan, Z., Wang, P., & Xiao, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s118982 · Cited by 41
Immunology in China: the past, present and future
Cao, X. (2008) · Nature Immunology · doi:10.1038/ni0408-339 · Cited by 38
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy
Li, Y., Wang, J., Li, C., & Ke, X. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.673228 · Cited by 38
Size-dependent gene delivery of amine-modified silica nanoparticles
Yu, M., Niu, Y., Zhang, J., Zhang, H., Yang, Y., Taran, E., Jambhrunkar, S., Gu, W., Thorn, P., & Yu, C. (2015) · Nano Research · doi:10.1007/s12274-015-0909-5 · Cited by 38
Self-citationMiller, W. H., Kim, T. M., Lee, C. B., Flaherty, K. T., Reddy, S. A., Jamal, R., Chow, L. Q. M., Rooney, I. A., Pitcher, B., Cha, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3057 · Cited by 27
Ethical Perspectives on RNA Interference Therapeutics
Ebbesen, M., Jensen, T. G., Andersen, S., & Pedersen, F. S. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.159 · Cited by 25
A potential biomarker for anti-PD-1 immunotherapy
Goswami, S., Basu, S., & Sharma, P. (2018) · Nature Medicine · doi:10.1038/nm.4489 · Cited by 18
Human immunodeficiency virus type 1 Tat induces B7-H1 expression via ERK/MAPK signaling pathway
Shi, J., Qin, X., Zhao, L., Wang, G., & Liu, C. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2011.07.005 · Cited by 13
Cited by
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.001 · Cited by 851
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 260
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Luo, L., Wang, X., Liao, Y.-P., Xu, X., Chang, C. H., & Nel, A. E. (2024) · Nano Today · doi:10.1016/j.nantod.2023.102058 · Cited by 16
Metadata
- Authors
- Wu, Y., Chen, W., Xu, Z. P., & Gu, W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-08-27
- Volume
- 10
- Pages
- 2022-2022
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2967658120
- Cited by
- 419
- References
- 114
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.